Disclosure CP has reported honoraria from Bayer, Janssen and Advanced Accelerator Applications (AAA) and research grants from Bayer; EC has reported honoraria from Astellas, AstraZeneca, Bayer, Janssen and Pfizer and research grants from AstraZeneca, Bayer and Janssen; KF has reported participation to advisory boards/honoraria for Astellas, AAA, Bayer, Clovis, Curevac, Incyte, Janssen, Merck Sharp & Dohme, Orion, Sanofi; AH has reported paid consultancy for Amgen, Astellas, Ferring, Ipsen, Jansen, Pfizer, Sanofi, Takeda and has received research grants from Astellas and Sanofi; PO has reported institutional honoraria from Janssen, Bayer, Ferring Pharmaceuticals for consultancy and research grants from Merck and Varian; GP has reported advisory boards/honoraria from AstraZeneca, Bayer, Bristol-Myers Squibb, Ipsen, Janssen, Merck Sharp & Dohme, Novartis and Pfizer; BT has reported paid consultancy for Amgen, Bayer, Astellas, Ferring Pharmaceuticals, Janssen, Sanofi-Genzyme, Steba and that he is an investigator for Bayer, Astellas, Ferring Pharmaceuticals, Myovant Sciences, Janssen, Sanofi-Genzyme and Steba; SG has reported advisory role (including independent data monitoring committees) and speakers bureau for AAA International, Active Biotech AB, Amgen, Astellas Pharma, Bayer, Bristol-Myers Squibb, CellSearch, Clovis, CureVac, Dendreon, ESSA Pharma, Ferring, Innocrin Pharmaceuticals, Janssen Cilag, MaxiVAX, Millenium, Nectar, Novartis, Orion, Pfizer, ProteoMediX, Roche, Sanofi, and has reported being the co-inventor for a method for biomarker discovery (on patent application WO 2009138392 A1, granted in China, Europe, Japan and the USA).